...
首页> 外文期刊>Diabetes care >The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes.
【24h】

The effect of trandolapril and its fixed-dose combination with verapamil on proteinuria in normotensive adults with type 2 diabetes.

机译:trandolapril及其固定剂量联合维拉帕米对2型糖尿病血压正常成人蛋白尿的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

OBJECTIVE-To compare the effect of fixed-dose trandolapril-verapamil (FDTV) with that of trandolapril on proteinuria in normotensive, type 2 diabetic patients. RESEARCH DESIGN AND METHODS-A total of 60 normotensive, type 2 diabetic patients with 24-h proteinuria >300 mg were randomly assigned to two groups for open-label treatment. One group received 2 mg trandolapril/180 mg verapamil FDTV once daily; the other group received 2 mg trandolapril once daily. Study drugs were administered for 6 months in both groups. Creatinine clearance and 24-h urinary protein excretion were measured at the beginning and the end of the study. Patients were evaluated monthly for blood pressure, fasting blood glucose level, heart rate, and adverse events. Statistical analysis was performed using ANOVA. RESULTS-Both groups experienced a statistically significant (P < 0.005) mean decrease in mean proteinuria from baseline: FDTV ([mean +/- SD] 1,200 +/- 200 to 540 +/- 79 mg; P < 0.001) and trandolapril (1,105 +/- 212 to 750.9+/- 134 mg; P < 0.005). A significantly greater reduction from baseline in proteinuria was observed in the FDTV group compared with the trandolapril group. Patients who received trandolapril experienced a statistically significant (P < 0.05) decrease in mean creatinine clearance (91.1 +/- 3.4 to 75.3 +/- 3 ml/min; P < 0.05) compared with patients who received FDTV (88.3 +/- 3.6 to 82.9 +/- 3.5 ml/min; P > 0.05). Final fasting blood glucose was significantly lower in the FDTV group (139 +/- 19) compared with the trandolapril group (154 +/- 22; P < 0.001). No significant differences were observed between the two groups in mean baseline or final measurements of blood pressure, mean heart rate, or frequency of adverse events. CONCLUSIONS-Our results suggest that FDTV is more effective than trandolapril in reducing proteinuria in normotensive, type 2 diabetic patients. This effect on proteinuria is not related with blood pressure reduction.
机译:目的-比较固定剂量的trandolapril-verapamil(FDTV)和trandolapril对正常血压的2型糖尿病患者蛋白尿的影响。研究设计和方法-将60例24小时蛋白尿> 300 mg血压正常的2型糖尿病患者随机分为两组进行开放标签治疗。一组每天接受一次2 mg trandolapril / 180 mg verapamil FDTV;另一组每天服用2 mg trandolapril。两组均给予研究药物6个月。在研究开始和结束时测量肌酐清除率和24小时尿蛋白排泄量。每月评估患者的血压,空腹血糖水平,心率和不良事件。使用ANOVA进行统计分析。结果-两组的平均蛋白尿均较基线平均下降有统计学意义(P <0.005):FDTV([平均值+/- SD] 1,200 +/- 200至540 +/- 79 mg; P <0.001)和trandolapril( 1,105 +/- 212至750.9 +/- 134毫克; P <0.005)。与trandolapril组相比,FDTV组的蛋白尿从基线水平明显降低。与接受FDTV的患者(88.3 +/- 3.6)相比,接受trandolapril的患者的平均肌酐清除率降低了统计学显着(P <0.05)(91.1 +/- 3.4至75.3 +/- 3 ml / min; P <0.05)。至82.9 +/- 3.5毫升/分钟; P> 0.05)。与trandolapril组(154 +/- 22; P <0.001)相比,FDTV组的最终空腹血糖明显降低(139 +/- 19)。两组的平均基线或最终血压,平均心率或不良事件发生率均无显着差异。结论-我们的结果表明,FDTV在降低血压正常的2型糖尿病患者的蛋白尿方面比trandolapril更有效。这种对蛋白尿的影响与血压降低无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号